Vanguard Group Inc. Boosts Stock Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Vanguard Group Inc. boosted its holdings in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,474,879 shares of the biotechnology company's stock after acquiring an additional 70,912 shares during the quarter. Vanguard Group Inc. owned 2.54% of Alpine Immune Sciences worth $16,887,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in shares of Alpine Immune Sciences by 99.1% during the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 1,315 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in Alpine Immune Sciences during the 3rd quarter worth approximately $35,000. Barclays PLC lifted its position in shares of Alpine Immune Sciences by 818.4% in the 4th quarter. Barclays PLC now owns 6,080 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 5,418 shares during the period. BNP Paribas Arbitrage SNC boosted its stake in shares of Alpine Immune Sciences by 88.7% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 3,090 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Alpine Immune Sciences by 26.8% during the second quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company's stock worth $62,000 after buying an additional 1,543 shares during the period. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Stock Up 0.1 %

NASDAQ ALPN traded up $0.05 during trading hours on Monday, hitting $64.42. The company had a trading volume of 3,550,120 shares, compared to its average volume of 1,861,311. Alpine Immune Sciences, Inc. has a 52 week low of $6.71 and a 52 week high of $64.57. The firm has a 50 day simple moving average of $36.42 and a 200 day simple moving average of $23.12.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. Research analysts anticipate that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALPN has been the topic of a number of research analyst reports. Leerink Partnrs cut shares of Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a research report on Thursday. SVB Leerink downgraded shares of Alpine Immune Sciences from an "outperform" rating to a "market perform" rating and lifted their price target for the company from $42.00 to $65.00 in a research note on Friday. Oppenheimer reiterated an "outperform" rating and issued a $44.00 price target (up previously from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Wolfe Research reissued a "peer perform" rating on shares of Alpine Immune Sciences in a research report on Thursday. Finally, HC Wainwright lowered Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a research report on Thursday. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $50.33.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.